Core Insights - Crown Castle reported revenue of $1.07 billion for the quarter ended September 2025, a decrease of 35.1% year-over-year, but exceeded the Zacks Consensus Estimate by 1.98% [1] - The company's EPS was $1.12, up from $0.70 in the same quarter last year, representing a surprise of 7.69% over the consensus estimate of $1.04 [1] Revenue Breakdown - Services and other revenue was $60 million, surpassing the average estimate of $52.25 million, with a year-over-year increase of 1.7% [4] - Site rental revenue was $1.01 billion, slightly above the estimated $998.97 million, but down 36.5% compared to the previous year [4] Earnings Performance - Net Earnings Per Share (Diluted) was reported at $0.74, exceeding the average estimate of $0.54 [4] - Gross margin for services and other was $30 million, compared to the estimated $23.77 million [4] - Gross margin for site rental was $762 million, above the estimated $750.04 million [4] Stock Performance - Crown Castle's shares returned +4.6% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Insights - Goosehead Insurance reported revenue of $90.44 million for the quarter ended September 2025, reflecting a year-over-year increase of 15.9% [1] - The earnings per share (EPS) for the quarter was $0.46, down from $0.50 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $92.39 million, resulting in a surprise of -2.11% [1] - The company experienced an EPS surprise of -2.13%, with the consensus EPS estimate being $0.47 [1] Key Company Metrics - Total Core Revenue was reported at $83.87 million, compared to the average estimate of $86.32 million, marking a year-over-year change of +14.1% [4] - Ancillary Revenue from Contingent Commissions was $4.54 million, slightly below the average estimate of $4.68 million, with a year-over-year increase of +82.4% [4] - Total Cost Recovery Revenue was $1.54 million, compared to the average estimate of $1.6 million, representing a year-over-year decline of -6.2% [4] - Total Ancillary Revenue reached $5.02 million, below the average estimate of $5.46 million, with a year-over-year increase of +74.6% [4] - Core Revenue from Agency Fees was $2.71 million, exceeding the average estimate of $2.56 million, reflecting a year-over-year increase of +36.5% [4] - Other Franchise Revenues amounted to $0.48 million, below the average estimate of $1.05 million, with a year-over-year change of +23.9% [4] - Initial Franchise Fees in Cost Recovery Revenue were $1.38 million, slightly above the average estimate of $1.3 million, showing a year-over-year decline of -2.3% [4] - Interest Income in Cost Recovery Revenue was $0.16 million, below the average estimate of $0.17 million, with a year-over-year decline of -29.9% [4] - New Business Royalty Fees in Core Revenue were $8.28 million, exceeding the average estimate of $7.94 million, with a year-over-year increase of +18.3% [4] - New Business Commissions in Core Revenue were $7.53 million, below the average estimate of $8 million, reflecting a year-over-year increase of +20.5% [4] - Renewal Royalty Fees in Core Revenue were $45.69 million, slightly above the average estimate of $45.32 million, with a year-over-year increase of +20% [4] - Renewal Commissions in Core Revenue were $19.67 million, below the average estimate of $21.6 million, representing a year-over-year decline of -2.7% [4] Stock Performance - Goosehead's shares have returned -11.8% over the past month, contrasting with the Zacks S&P 500 composite's +1.1% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - GE Vernova Inc. reported third-quarter revenue of $9.97 billion, exceeding analyst expectations of $9.16 billion, representing a 12% year-over-year increase, but adjusted earnings per share were $1.64, below the expected $1.86 [1][2] Revenue and Earnings - The company reaffirmed its 2025 full-year revenue outlook, expecting to reach the upper end of its $36–$37 billion range, slightly below the $37.15 billion consensus [2] - Orders surged 55% organically to $14.6 billion, driven by strong demand in the Power and Electrification segments [2] Backlog and Orders - The backlog increased by $6.6 billion sequentially, with Gas Power equipment reservations rising from 55 to 62 gigawatts [2] - By segment, Power orders rose 50% organically to $7.8 billion, with revenue up 15% to $4.8 billion [3] - Wind orders increased 4% to $1.8 billion, although revenue fell 8% to $2.6 billion [3] - The Electrification unit saw orders more than double to $5.1 billion, while revenue advanced 35% to $2.6 billion [3]

Take a Trial Today BREAKING: Gold Prices, Stocks Continue To Slide Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! It's Tesla (TSLA) earnings day with the EV giant reporting third-quarter financials after the stock market close Wednesday, with all attention on CEO Elon Musk and the conference call. At a glance, analyst consensus pegs third-quarter EPS falling 22% to 56 cents vs. 72 cents in Q3 2024, according to FactSet. Reven ...

Tesla is scheduled to report its third-quarter financial results after the bell on Wednesday, Oct. 22. Once the market closes, the company will issue a brief advisory with a link to its third-quarter results and guidance, which will be available on the company’s investor relations website. Although Tesla experienced a decline in revenue earlier this year while CEO Elon Musk partnered with President Donald Trump to spearhead the Department of Government Efficiency, Tesla has steadily recovered since Musk a ...

Core Insights - Cencora, Inc. is a leading global healthcare solutions provider with a market cap of $63.8 billion, focusing on sourcing and distributing pharmaceutical and healthcare products while offering logistics, data analytics, and commercialization services [1] Financial Performance - Cencora is expected to announce its fiscal Q4 2025 results on November 5, with analysts forecasting an adjusted EPS of $3.79, representing a 13.5% increase from $3.34 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $15.93, reflecting a 15.8% increase from $13.76 in fiscal 2024 [3] Stock Performance - Cencora's shares have increased by over 39% in the past 52 weeks, outperforming the S&P 500 Index's rise of 15.1% and the Health Care Select Sector SPDR Fund's decline of 4.1% during the same period [4] Recent Results and Challenges - In Q3 2025, Cencora reported an adjusted EPS of $4 and revenue of $80.66 billion, but shares fell by 2.9% due to a 12.9% decline in operating income from the International Healthcare Solutions segment, increased interest expenses of $81.8 million (up $50.5 million), and a 17.3% rise in operating expenses [5] Analyst Ratings - The consensus rating for Cencora's stock is bullish, with a "Strong Buy" rating from 11 out of 15 analysts, while four analysts recommend a "Hold" rating. The average price target is $339.71, indicating a potential upside of 3.3% from current levels [6]

Core Insights - Gilead Sciences, Inc. is a biopharmaceutical company focused on developing medicines for unmet medical needs, with a market cap of $152.8 billion [1] - The company is expected to announce its fiscal third-quarter earnings for 2025 on October 30, 2023 [1] Financial Performance - Analysts anticipate Gilead to report a profit of $2.15 per share for the upcoming quarter, reflecting a 6.4% increase from $2.02 per share in the same quarter last year [2] - For the full fiscal year, Gilead's EPS is projected to be $8.07, a significant increase of 74.7% from $4.62 in fiscal 2024, with an expected rise to $8.51 in fiscal 2026 [3] Stock Performance - Gilead's stock has outperformed the S&P 500 Index, gaining 43.8% over the past 52 weeks compared to the index's 15.1% increase [4] - The stock also significantly outperformed the Health Care Select Sector SPDR Fund, which experienced a 4.1% decline during the same period [4] Business Drivers - The company's strong performance is attributed to sales growth in HIV treatments, Livdelzi, and Trodelvy, despite declines in HCV and Veklury sales [5] - The approval of lenacapavir enhances Gilead's HIV portfolio, particularly as Truvada faces generic competition, with key products including Biktarvy and Descovy [5] Analyst Sentiment - The consensus opinion on Gilead stock is moderately bullish, with a "Moderate Buy" rating from analysts; 19 out of 29 analysts recommend a "Strong Buy" [7] - The average analyst price target for Gilead is $127.54, indicating a potential upside of 2.8% from current levels [7]

Core Insights - Pinnacle West Capital Corporation (PNW) is a utility holding company based in Phoenix, Arizona, providing retail and wholesale electric services, with a market cap of $11.1 billion [1] - The company is expected to announce its fiscal third-quarter earnings for 2025 on November 3, 2025 [1] Earnings Expectations - Analysts predict PNW will report a profit of $2.89 per share on a diluted basis, representing a 14.2% decline from $3.37 per share in the same quarter last year [2] - For the full fiscal year, EPS is expected to be $4.55, down 13.2% from $5.24 in fiscal 2024, but is projected to rise 3.1% year over year to $4.69 in fiscal 2026 [3] Stock Performance - PNW stock has underperformed the S&P 500 Index, which gained 15.1% over the past 52 weeks, with PNW shares only increasing by 5.5% during the same period [4] - The stock also lagged behind the Utilities Select Sector SPDR Fund, which saw an 11% gain in the same timeframe [4] Recent Financial Results - In Q2, PNW reported an EPS decline of 10.2% year over year to $1.58, with revenue at $1.4 billion, reflecting a 3.8% year-over-year increase [5] - The company anticipates full-year EPS to be between $4.40 and $4.60 [5] Analyst Ratings - The consensus opinion on PNW stock is moderately bullish, with a "Moderate Buy" rating overall; out of 16 analysts, five recommend a "Strong Buy," ten suggest a "Hold," and one advises a "Strong Sell" [6] - The average analyst price target for PNW is $97, indicating a potential upside of 5.2% from current levels [6]

Core Insights - Howmet Aerospace Inc. (HWM) has a market capitalization of $73.2 billion and specializes in engineered metal products for aerospace, defense, and industrial markets [1] - The company is expected to report an adjusted EPS of $0.91 for fiscal Q3 2025, reflecting a 28.2% increase from $0.71 in the same quarter last year [2] - For fiscal 2025, analysts forecast an adjusted EPS of $3.59, which is a 33.5% increase from $2.69 in fiscal 2024 [3] Stock Performance - HWM stock has increased by 85.5% over the past 52 weeks, outperforming the S&P 500 Index's return of 15.1% and the Industrial Select Sector SPDR Fund's gain of 11.6% during the same period [4] - On September 30, Howmet Aerospace announced a dividend of $0.12 per share, which will be payable on November 25, 2025, indicating the company's commitment to returning capital to shareholders [5] Analyst Ratings - The consensus among analysts is bullish, with a "Strong Buy" rating overall; 17 out of 22 analysts recommend a "Strong Buy," one suggests a "Moderate Buy," and four provide a "Hold" rating [6] - The mean price target for HWM is $210.67, representing a premium of 6.8% from current market prices [6]

Core Insights - Agree Realty (ADC) reported a revenue of $183.22 million for the quarter ended September 2025, marking an 18.7% year-over-year increase and exceeding the Zacks Consensus Estimate of $179.46 million by 2.1% [1] - The company achieved an EPS of $1.10, compared to $0.42 a year ago, with a surprise of 1.85% over the consensus estimate of $1.08 [1] Revenue Performance - Rental income was reported at $183.19 million, surpassing the average estimate of $171.45 million from two analysts, reflecting an 18.7% year-over-year increase [4] - Operating cost reimbursement revenue was $19.84 million, exceeding the estimated $18.2 million, and showing a 23.2% increase compared to the previous year [4] Earnings Metrics - Net Earnings Per Share (Diluted) was reported at $0.45, matching the average estimate from four analysts [4] - The stock has returned +6.9% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change, indicating strong market performance [3]